Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not a subscriber? Subscribe now for unlimited access to online articles.

Business Impact

Biogen Idec ends exploration of a possible sale after failing to attract offers, stock plunges

Biotechnology company Biogen Idec Inc. said Wednesday it did not receive any definitive buyout offers during a recent strategic review and will remain an independent company.

The stock plunged 26 percent to $55.92 in after-hours trading after closing at $75.88.

The company announced its intention Oct. 12 to explore the possibility of a sale. It already had interest from billionaire investor Carl Icahn. Wall Street speculated that potential buyers could include Pfizer Inc., GlaxoSmithKline PLC, Sanofi-Aventis, and Novartis AG.

”The board (of directors) emphasized that Biogen Idec’s business strategy is working and generating strong operating and financial performance,” the company said in a statement. ”The board noted that it is confident that continued execution of the company’s business plan will result in attractive value for stockholders.”

The company was represented by Goldman Sachs & Co. and Merrill Lynch & Co. throughout the process.

Countdown to EmTech MIT 2019. Join us as we unveil the Innovators Under 35

Register now
More from Business Impact

How technology advances are changing the economy and providing new opportunities in many industries.

Want more award-winning journalism? Subscribe to MIT Technology Review.
  • Print + All Access Digital {! insider.prices.print_digital !}* Best Value

    {! insider.display.menuOptionsLabel !}

    The best of MIT Technology Review in print and online, plus unlimited access to our online archive, an ad-free web experience, discounts to MIT Technology Review events, and The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Unlimited access to all our daily online news and feature stories

    6 bi-monthly issues of print + digital magazine

    10% discount to MIT Technology Review events

    Access to entire PDF magazine archive dating back to 1899

    Ad-free website experience

    The Download: newsletter delivery each weekday to your inbox

    The MIT Technology Review App

  • All Access Digital {! insider.prices.digital !}*

    {! insider.display.menuOptionsLabel !}

    The digital magazine, plus unlimited site access, our online archive, and The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Unlimited access to all our daily online news and feature stories

    Digital magazine (6 bi-monthly issues)

    Access to entire PDF magazine archive dating back to 1899

    The Download: newsletter delivery each weekday to your inbox

  • Print Subscription {! insider.prices.print_only !}*

    {! insider.display.menuOptionsLabel !}

    Six print issues per year plus The Download delivered to your email in-box each weekday.

    See details+

    12-month subscription

    Print magazine (6 bi-monthly issues)

    The Download: newsletter delivery each weekday to your inbox

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.